Journal of Hematology & Oncology

Article	Citations
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects	913
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China	883
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and	861
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024	847
Recent advances in targeting protein degradation for tumor immunotherapy	793
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans	597
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma	448
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018	432
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening	386
Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases	363
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ	358
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency	355
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies	346
Cytokines and cancer-associated fibroblasts	334
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	333
Cancer vaccines: current status and future directions	301
Landscape of biallelic DNMT3A mutant myeloid neoplasms	300
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	299
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients	288
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration	254
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)	253
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway	241
HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors	240
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p	238
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1	237

Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis	236
Personalized nanovaccines for treating solid cancer metastases	221
A modular γδ TCR-T platform combining KRAS pMHC targeting with re-dosable mRNA engager redirection	218
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma	210
Ferroptosis: principles and significance in health and disease	210
Recent advances in therapeutic strategies for non-small cell lung cancer	209
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts	209
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model	198
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs	198
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis	196
Multiple myeloma risk linked to DNA damage response genes	193
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global	192
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	187
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis	186
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy	179
Recent advances in targeted strategies for triple-negative breast cancer	175
CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies	174
Small RNA modifications: regulatory molecules and potential applications	171
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	169
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry	163
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer	162
The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials	155
Emerging artificial intelligence advances in oncology: latest updates from the 2026 AACR annual meeting	154
Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting	152
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts	152
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment	149
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response	147
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages	146
Target neutrophil heterogeneity and plasticity in cancer	143
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia	142
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers	141
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia	141
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation	139
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives	137
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study	135
A single-cell and spatially resolved atlas of human osteosarcomas	135
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis	134
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting	133
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects	129
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting	126
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia	122
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting	120
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies	118
The functional and clinical roles of liquid biopsy in patient-derived models	115
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia	114
Echinomycin as a promising therapeutic agent against KSHV-related malignancies	113
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting	109
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting	109
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial	107
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy	106

C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function	106
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II	105
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis	103
Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies	100
Gastric cancer treatment: recent progress and future perspectives	100
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives	98
Challenges and new technologies in adoptive cell therapy	98
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives	98
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT	96
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial	94
CD20-directed antibody-drug conjugates in non-hodgkin lymphoma: translating preclinical promise into clinical reality	91
The DAPK3-DCAF1 pathway regulates ZBP1 protein stability to orchestrate PANoptosis for ovarian cancer therapy	90
METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation	89
Targeting GPRC5D for multiple myeloma therapy	88
Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and po	87
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation	85
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients	83
Metabolic reprogramming in the tumor microenvironment of liver cancer	83
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors	83
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms	83
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal	81
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain	79
Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis	78
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	78
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	77
Correction : LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis	77
Correction: Immunosenescence: a key player in cancer development	75
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease	75
PSMA-targeted CAR-macrophages drive glycolytic reprogramming for enhanced prostate cancer immunotherapy	73
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC	73
The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications	71
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy	70
Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer	70
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study	69
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned	69
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress	69
Advances in targeting histone deacetylase for treatment of solid tumors	67
Racial disparities in clonal hematopoiesis and their impact on hematologic malignancies	65
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy	65
Retraction Note: AMLnet, A deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears	63
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry	61
Long-term control of peritoneal metastases following claudin 18.2-targeted CAR T-Cell therapy in advanced gastric cancer	60
Targeting ERRα promotes cytotoxic effects against acute myeloid leukemia through suppressing mitochondrial oxidative phosphorylation	60
Cancer stem cell plasticity: mechanisms, immune microenvironment crosstalk, and therapeutic implications	60
Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma	59
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT	57
Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021	57
Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lympho	56
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies	56
The neuro-immune axis in cancer: from mechanisms to therapeutic opportunities	55
Integrated clinical and proteomic-based model for diagnostic and prognostic prediction in pRCC	55
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	55
Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation	51
Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies	50
Luspatercept and imetelstat for myelodysplastic syndrome: updates from ASH 2025 annual meeting	50
The distinct roles of ROS in tumor immunity: from mechanisms to immunotherapeutic applications	50
Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study	48
Targeting inflammation as cancer therapy	48
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades	47
Optimizing next-generation CAR-macrophages against solid tumors: challenges and potential strategies	46
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics	46
Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study	46
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy	46
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies	45
Spatial imaging unlocks the potential of charting multiple myeloma and extramedullary disease	45
Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma	44
Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolyt	43
Multiscale protein networks systematically identify aberrant protein interactions and oncogenic regulators in seven cancer types	42
Lung cancer vaccines to enhance immune checkpoint inhibitor therapy: evidence and future perspectives	42
Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead	42
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease	41
Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting	41
Agent-specific, histopathology-stratified hematologic malignancy risk among dpp-4 inhibitors, glp-1 receptor agonists, and SGLT2 inhibitors: a network meta-analysis of 270,471 participants	40
BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting	39
Mitophagy’s impacts on cancer and neurodegenerative diseases: implications for future therapies	37
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting	37
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy	37
From tumor targeting to tumor accessibility: surface-engineered bacteria as precision living therapeutics for translational medicine	36
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2	36
Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies	36

Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed pri	36
Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis	36
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting	36
CBX3 confers ferroptosis resistance during blood-borne metastasis	35
Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells	35
Novel strategies for cancer immunotherapy: counter-immunoediting therapy	35
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy	35
Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma	35
Genitourinary cancers updates: highlights from ASCO 2023	35
A novel tRNA-derived fragment tRF-3022b modulates cell apoptosis and M2 macrophage polarization via binding to cytokines in colorectal cancer	35
Molecularly targeted therapy and immunotherapy in leukemias	35
Involvement of inflammasomes in tumor microenvironment and tumor therapies	34
CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial	34
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium	34
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents	34
Disruption of the sorcin‒PAX5 protein‒protein interaction induces ferroptosis by promoting the FBXL12-mediated ubiquitination of ALDH1A1 in pancreatic cancer	34
Implementing generative artificial intelligence in precision oncology: safety, governance, and significance	34
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma	34
Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-speci	34
Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021: a systematic analysis for the GBD 2021	31
Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia	30
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression	30
The R-RAS2 GTPase is a signaling hub in triple-negative breast cancer cell metabolism and metastatic behavior	29
Cardiovascular adverse events associated with bispecific antibodies in relapsed or refractory B-cell non-Hodgkin lymphomas	29
Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms	29
Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant	29
Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated resu	29
Non-canonical small noncoding RNAs in the plasma extracellular vesicles as novel biomarkers in gastric cancer	28
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR	28
Consensus, debate, and prospective on pancreatic cancer treatments	28
Recent advances in therapeutic strategies for triple-negative breast cancer	28
Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance	27
Liquid biopsy: current technology and clinical applications	27
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers	27
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment	27
PD-1 blockade immunotherapy as a successful rescue treatment for disseminated adenovirus infection after allogeneic hematopoietic stem cell transplantation	27
Correction: The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications	27
CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022	27
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation	27
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial	27
Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013	27
Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors	26
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality	26
Emerging advances in CAR-T therapy for solid tumors: latest clinical trial updates from 2025 ASCO annual meeting	26
PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair	26
Targeting FGFR for cancer therapy	25
Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting	25
Harnessing immunotherapy for brain metastases: insights into tumor–brain microenvironment interactions and emerging treatment modalities	25
Lipid-based nanosystems: the next generation of cancer immune therapy	25
LncRNA-encoded peptides in cancer	25
Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial	24
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia	24
Retraction Note: Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor	24
Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies	23
The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives	23
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies	23
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021	23
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA	23
Novel research and future prospects of artificial intelligence in cancer diagnosis and treatment	23
In vivo CAR-T cell therapy: latest updates from 2025 ASH annual meeting	23
Recent advances in S-palmitoylation and its emerging roles in human diseases	22
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia	22
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors	22
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Conso	22
FIT-based risk-stratification model effectively screens colorectal neoplasia and early-onset colorectal cancer in Chinese population: a nationwide multicenter prospective study	22
Dual-modular-nanobody CAR-T cell technical platform against the solid tumor microenvironment	22
Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT	22
B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia	22
Targeting CD276 with Adapter-CAR T-cells provides a novel therapeutic strategy in small cell lung cancer and prevents CD276-dependent fratricide	21
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells	21
Necroptosis in cancer: insight from epigenetic, post-transcriptional and post-translational modifications	21
Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis	21
Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed/refractory acute myeloid leukemia	21
Correction: CD44 standard and CD44v10 isoform expression on leukemia cells distinctly influences niche embedding of hematopoietic stem cells	20
Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: results from a randomized, multicenter, placebo-controlled phase	20
Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization	20
Protein degradation: expanding the toolbox to restrain cancer drug resistance	20
Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL	20
Advances in first-line treatment for primary central nervous system lymphoma: highlights from the 2025 ASH annual meeting	20
Emerging evidence and treatment paradigm of non-small cell lung cancer	20
CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting	19
Correction: Naturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: from molecular mechanisms to potential therapeutic targets	19
Correction: myCAF-derived Exosomal PWAR6 accelerates CRC liver metastasis via altering glutamine availability and NK cell function in the tumor microenvironment	19
Evolving antibody-drug conjugates in breast cancer from precision delivery to tumor microenvironment reprogramming	19
FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma	19
Clinical development of mRNA therapies against solid tumors	19
Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study	19
Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy	18
Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases	18
IL-5 CAR-T cell therapy induces effective remission in hypereosinophilic disorders	18
Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia	18
Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity	18
Global cancer statistics for adolescents and young adults: population based study	18
Cancer associated fibroblasts in cancer development and therapy	17
Treatment-related adverse events of antibody drug-conjugates in clinical trials	17